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Abstract
OBJECTIVE—Fecal microbiota transplantation (FMT) has been suggested as a new treatment to
manage Clostridium difficile infection (CDI). With use of a mathematical model of C. difficile
within an intensive care unit (ICU), we examined the potential impact of routine FMT.
DESIGN, SETTING, AND PATIENTS—A mathematical model of C. difficile transmission,
supplemented with prospective cohort, surveillance, and billing data from hospitals in the
southeastern United States.
METHODS—Cohort, surveillance, and billing data as well as data from the literature were used
to construct a compartmental model of CDI within an ICU. Patients were defined as being in 1 of
6 potential health states: uncolonized and at low risk; uncolonized and at high risk; colonized and
at low risk; colonized and at high risk; having CDI; or treated with FMT.
RESULTS—The use of FMT to treat patients after CDI was associated with a statistically
significant reduction in recurrence but not with a reduction in incident cases. Treatment after
administration of high-risk medications, such as antibiotics, did not result in a decrease in
recurrence but did result in a statistically significant difference in incident cases across treatment
groups, although whether this difference was clinically relevant was questionable.
CONCLUSIONS—Our study is a novel mathematical model that examines the effect of FMT on
the prevention of recurrent and incident CDI. The routine use of FMT represents a promising
approach to reduce complex recurrent cases, but a reduction in CDI incidence will require the use
of other methods to prevent transmission.
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Clostridium difficile is a frequent source of healthcare-associated infections (HAIs),
especially among patients who receive treatment regimens that involve antibiotics1 or proton
pump inhibitors (PPIs)2,3 or who have other conditions that disrupt normal gut microbiota.
The rate of C. difficile infection (CDI) in the United States has been increasing since 2000,
and CDI caused an estimated 336,565 cases in 2009.4 In some healthcare facilities, CDI has
eclipsed methicillin-resistant Staphylococcus aureus as the leading source of HAI.5 Of
special concern is the development of recurrent CDI, which may be a complicated, long-
term condition typified by repeated bouts of severe diarrhea.
Because altering the indigenous microbiota of the intestinal tract causes CDI, there has been
an interest in recolonizing the intestinal tract with introduced donor bacteria obtained from
either healthy donor stool6,7 or a synthetically derived pure culture.8 This procedure,
referred to as fecal microbiota transplantation (FMT), restores the bacterial ecology that
keeps C. difficile in check. Both uncontrolled case reports7,8 and a small clinical trial6 have
shown encouraging results; however, FMT is still largely reserved for specialized
intervention in difficult or refractory cases. Furthermore, the implications of routine
intestinal recolonization as a standard course of treatment for the prevention of recurrent or
incident CDI have not been widely explored. The need for an increased understanding of the
potential effects and utility of FMT is especially urgent in light of the US Food and Drug
Administration’s increased interest in the procedure and their decision that it falls under the
agency’s regulatory purview.9
Mathematical models are ideal for studying such hypothetical scenarios. They can provide a
repeatable, quantitative environment with which to evaluate evidence, guide policy creation,
discover critical thresholds upon which the success of interventions may depend, and
suggest new directions for observational studies and clinical trials. These strengths are
difficult or impossible to duplicate with empirical research within a hospital. Critically, one
patient’s outcome influences another’s exposure, which violates traditional statistical
assumptions of independence. Finally, mathematical models are capable of scaling up the
independent, individual-level observations that emerge from clinical research to the
population level. In this way, we may study how these individuals interact with one another
and influence the transmission process without a risk to patient safety. To evaluate the
impact of routine intestinal microbiota recolonization in patients with CDI, we developed a
mathematical model that describes the transmission of C. difficile within an intensive care
unit (ICU) and has the capability to test the impact of FMT on prevention of recurrent or
initial C. difficile infection due to in-hospital transmission.
METHODS
Data
Hospital data were obtained from 3 separate sources, each consisting of patient records
between July 1, 2009, and December 31, 2010. The first data set was a cohort of 609 adult
patients with incident CDI extracted from prospectively collected HAI surveillance data
from 28 community hospitals in the Duke Infection Control Outreach Network (DICON).10
This data set included admission, discharge, and diagnosis times; outcomes that included
death and discharge; and patient demographic characteristics. The second data set included
weekly surveillance time series from 31 DICON-affiliated hospitals within the DICON
network, consisting of the overall number of hospital-onset, healthcare facility–associated
CDI cases classified by infection preventionists at DICON member hospitals using Centers
for Disease Control and Prevention surveillance criteria,11 whole hospital patient-day
denominator data, ICU patient-days, and whether the hospital was using a nonmolecular
diagnostic test or a diagnostic test based on polymerase chain reaction (PCR). In total, these
series consist of 1,805 cases and 344,471 ICU patient-days. Finally, a third data set included
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hospital billing records for 452 inpatients discharged from the ICU within the University of
North Carolina (UNC) Healthcare System, consisting of discharge times; orders for drugs
that place patients at risk for CDI, such as PPIs or fluoroquinolones; coded diagnoses
present at hospital admission; and demographic characteristics.
Transmission Model
The transmission of C. difficile through an ICU was modeled as a series of compartments
representing patient health and treatment states (Figure 1). Healthcare personnel (HCP) were
modeled as being either uncontaminated (US) or contaminated (H), representing hands or
gloves contaminated by vegetative C. difficile or spores. Patients could be in 1 of 6
compartments. Compartment UP represented uncolonized patients who were not receiving
high-risk medication for CDI, and UA represented uncolonized patients who were receiving
high-risk medications. Similarly, CP and CA represented low-risk and high-risk patients who
had previously been exposed to the organism. Compartment D represented patients who had
developed CDI. Finally, some of the scenarios we considered had an additional
compartment, CT, which represented patients under prophylactic treatment using FMT
administered via colonoscopy to prevent an initial infection.
The interactions and transitions between these compartments were governed by a series of 8
differential equations (detailed in the Appendix). Patients were admitted into UP, UA, CP,
CA, or D. Colonized patients (CP and CA) and patients with CDI (D) shed infectious
material that may contaminate hands of HCP, and uncontaminated patients (UP and UA) are
subsequently colonized when cared for by HCP with contaminated hands. HCP could
decontaminate their hands by washing them after contact with either the patient or the
environment immediately surrounding them.
Because there is evidence of a surface contamination component to C. difficile
transmission,12 contacts between patients and HCP were modeled as direct care tasks, which
could involve contact with the patient environment as well as physical interaction between
the patient and HCP. Once colonized, patients could progress to CDI (CX to D). All patients
were eventually discharged from the hospital. Three possible outcomes were tracked for
patients with CDI: death, discharge from the hospital in good health, and discharge from the
hospital with subsequent development of recurrent CDI.
The model made several simplifying assumptions. First, all HCP were assumed to interact
with all patients within the ICU, and patients were assumed not to interact with each other. It
is not known whether disruption of intestinal microbiota places patients at greater risk for
developing CDI once colonized or at greater risk for colonization and thus for subsequent
infection.13,14 Therefore, colonization once exposed to C. difficile and development of
infection after colonization is treated as a single process within the model. Additionally, we
assumed that patients who were treated with antibiotics or PPIs were prescribed those
medications immediately on arrival into the ICU. Additionally, we assumed that the
medication-induced disruption of the normal gut microbiota was immediate and lasted
beyond the discontinuation of treatment. This effectively meant that, once a patient was
classified as at high risk, they remained so unless an active intervention was made to
recolonize their intestinal tract.
Parameterization and Model Calibration
The transmission model was parameterized using a combination of estimates from the
literature and the data sets discussed above. Specific values and the sources that they are
derived from are described in Table 1. Rates of death and discharge for patients with CDI
were estimated from the DICON cohort data, whereas rates of discharge, use of antibiotics
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and PPIs, and the prevalence of C. difficile infection present at admission were all estimated
from the UNC Healthcare in-patient billing data.
The underlying hazard of developing CDI for low-risk patients was estimated by fitting a
deterministic version of the mathematical model above to the DICON surveillance time
series. On the basis of previous research indicating a 56% increase in the number of reported
cases within those hospitals that switched from nonmolecular to PCR diagnostic tests,15 case
numbers were inflated by 1.56 for weeks during which nonmolecular tests were in use. This
adjusted time series was then transformed into a weighted average of the cumulative number
of CDI cases in the 31 DICON hospitals to estimate a typical level of infection, which the
model was fit to using least squares to obtain the hazard of developing CDI in colonized
low-risk patients.
Simulations
The mathematical model described above was applied to a single 12-bed ICU consisting of
single patient rooms with 4 registered nurses and a single intensivist, based on average size
and staffing information and best-practice guidelines for ICUs.16–18 Admissions were fixed
to be equal to discharges to maintain a steady patient population. Several different potential
treatment regimens were considered (Table 2). First, we created a baseline scenario,
modeling no routine use of fecal transplantation. Second, we modeled a series of scenarios
depicting the systematic use of FMT after CDI to prevent recurrent cases, treating 20%,
40%, 60%, 80%, and 100% of cases. Third, we modeled a series of scenarios examining the
use of FMT prophylactically to prevent incident infections, treating contaminated high-risk
(CA) patients immediately after the conclusion of their treatment regimen, moving them to a
new, low-risk category (CT). These scenarios considered treating 20%, 40%, 60%, 80%, and
100% of all high-risk patients or just those patients who received fluoroquinolone
antibiotics. Finally, a combination strategy was examined, treating patients with FMT both
after CDI and after receipt of high-risk medication.
Deterministic models do not fully capture the transmission dynamics of small populations,
such as the experience of a single, 12-bed ICU. Therefore, each of the treatment scenarios
described above were modeled using 1,000 stochastic simulations of the equation system by
means of the Gillespie direct method.19 The effect of this is twofold. First, individuals
within the models are treated as discrete units (ie, no fractions of patients exist in
compartments). Second, because individuals are treated as discrete units and the model
becomes probabilistic, variations attributable to random chance may arise. These random
fluctuations play an important role in disease dynamics when modeling a small population.
The simulations were run over a 1-year time span.
Two primary outcomes were tracked in all scenarios: the number of incident infections, and
the number of infections that developed into recurrent cases. Note that, in many simulations,
we expected the number of recurrent cases to be higher than the number of incident
infections. The model handled both incident infections that arise in the ICU and prevalent
infections at admission, both of which could develop into recurrence. The results of
stochastic models are frequently non-normally distributed, and differences between
treatment groups were analyzed with nonparametric Kruskal-Wallis tests. Simulations were
written in Python 2.7, and all statistical analysis was performed in R, version 2.15.
RESULTS
The median and 25th and 75th percentile numbers of recurrent and incident cases for all
modeled scenarios are reported in Table 2. The baseline, no-intervention model produced
results similar to the known epidemiology of CDI. Infection rates were low, but periodic
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outbreaks of C. difficile occurred, as did periods of no infection. Despite high levels of
patient colonization and sustained transmission of C. difficile within the ICU, hand
contamination of HCP was rare and short lived. An example showing the development of a
typical simulation over time is shown in Figure 2.
The impact of FMT in preventing recurrence among different proportions of patients after
CDI is shown in Figure 3. The treatment resulted in a statistically significant (P < .001)
difference in the number of recurrences among the different treatment groups. The median
number of recurring cases ranged from 2 (interquartile range [IQR], 0–6) for no treatment to
a median of 0 (IQR, 0–1) when 100% of patients were treated. Treatment did not result in a
significant difference in the number of incident infections, regardless of what proportion of
patients were treated (P = .39). The median number of incident cases was 0 for all scenarios
(IQR, 0–1).
The results of scenarios in which patients were treated prophylactically after discontinuation
of antibiotic therapy or PPIs had very similar results to one another. Figure 4 shows the
results of the latter scenario for different proportions of treatment. Neither approach resulted
in a statistically significant difference in recurrence, regardless of the proportion treated (P
= .36 and .56, respectively); all scenarios had a median of 2 recurrent cases except for the
scenario with 60% treatment, which had a median of 1 recurrent case.
The difference in incident infections was statistically significant both when the treatment
group was limited to patients who received antibiotics over all levels of treatment (P = .004)
and to patients who received antibiotics, PPIs, or both (P = .001). In both treatment
scenarios, however, this difference did not result in tangibly different model outcomes from
a clinical perspective. In scenarios in which only patients who received antibiotics were
treated, all treatment levels had a median of 0 incident cases (IQR, 0–1). Simulations with
0% treatment did have a higher maximum number of incident cases (n = 12) than did models
in which 20%–100% of cases were treated (n = 9, 7, 9, 7, and 9, respectively). Similar
patterns were seen for simulations in which patients who received both antibiotics and PPIs
were treated (data not shown).
Combining both prophylactic treatment and postinfection treatment protocols resulted in a
statistically significant difference in recurrent cases over the proportion of patients treated (P
< .001). The median number of recurring cases ranged from 2 (IQR, 0–6) for no treatment to
a median of 0 (IQR, 0–1) when all patients were treated. This strategy also resulted in a
statistically significant difference in incident infections (P = .02), although, as with the
purely prophylactic scenarios, this difference did not manifest in a change in median
incidence, because all treatment levels had a median number of cases of 0 (IQR, 0–1).
However, the no-treatment scenario had a higher maximum number of incident cases (n =
12) compared with treatment levels of 20%–100% (n = 9, 8, 8, 7, and 8, respectively). These
results are shown in Figure 5.
DISCUSSION
Our unique study using mathematical modeling found that the widespread use of FMT
resulted in a marked reduction in the number of patients discharged from the hospital who
would go on to develop recurrent cases of CDI. Importantly, this reduction was seen in all
modeled scenarios ranging from relatively low levels of treatment (20% of patients) to very
high levels of treatment (100% of patients) with no apparent threshold effect. This
widespread evidence of a positive effect suggests that these results should be robust not only
to varying levels of treatment but also to lower levels of efficacy, because the two are
mathematically equivalent. Future research should evaluate the costs associated with these
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procedures, to assess whether the decrease in recurrent cases of CDI offsets the economic
costs of treatment as well as the risk to the patient. However, given the paucity of empirical
studies to establish rates of complication and the lack of an established standard route of
FMT administration, no cost-benefit component was included in this preliminary study.
Unsurprisingly, because treatment after CDI to prevent recurrent cases is a process that
occurs entirely after infection, the modeled intervention had very little impact on incident
hospital-acquired infections. Some secondary effects may be seen if fecal transplantation
becomes a regularly used treatment and results in a reduced number of recurrent cases and
fewer admissions with prevalent recurring C. difficile infection. Capturing this phenomenon
would require modeling not only a single ward but an entire local healthcare system, which
is beyond the scope of this study.
The evidence for a positive effect of using FMT after high-risk medications to prevent
incident infection is less apparent. Although treating patients who are receiving antibiotics
or both antibiotics and PPIs resulted in statistically significant or nearly significant results at
an α = 0.05 level, these results appear to have little tangible clinical impact on the number of
incident infections and no impact on the occurrence of recurrent infections. There is also
very little evidence for a synergistic effect between the 2 treatment strategies. Scenarios that
explored the simultaneous use of FMT after CDI and high-risk medication had results that
were very similar to those of FMT use after CDI alone. Taken as a whole, these results
indicate that routine use of fecal transplantation represents a promising tool to prevent
complicated, recurring episodes of CDI, but techniques to recolonize the intestinal tract
alone will be insufficient to contain the spread of C. difficile within a hospital ward.
This study is not without limitations. The model is limited to a single ICU in isolation.
Although this limited scope allows it to specifically address the complex problems presented
in critical care infection control, it is incapable of detecting effects in the hospital as a whole
brought about by altering transmission and recurrence within the ICU. Many of the states
within the model, such as whether or not a patient has come into contact with C. difficile, are
not regularly observed within hospitals, and thus some of the outcomes of the model cannot
be directly verified. As with all mathematical models, the results of the study are dependent
on the assumptions about the natural history of CDI and the values of the parameters used.
The purpose of this study, however, is not to provide precise predictions of future levels of
infection but to examine the overall impact of fecal transplantation as a routine treatment
option when dealing with C. difficile. Within this scope, the model structure and parameter
estimates represent the state-of-the-art knowledge of in-hospital C. difficile transmission.
Similarly, the parameter values chosen are not meant to emulate a particular hospital but to
provide a reasonable approximation of the experience of an ICU staffed by HCP following
good infection control practices.
This study represents, to the best of our knowledge, the first use of a mathematical model to
quantify the potential effects of fecal transplantation for the treatment and prevention of
CDI. These types of models represent a useful method for evaluating the potential impact of
new treatment approaches in areas of limited clinical and empirical evidence. Our results
suggest that routine intestinal recolonization is a powerful tool for the prevention of
recurrent infection. When combined with other infection control measures, such as improved
surface disinfection and antibiotic stewardship, fecal transplantation has great potential to
produce a substantial reduction in the burden of C. difficile, especially in reducing highly
morbid and difficult-to-manage recurrent infections.
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The system differential equations that describe the dynamics of Clostridium difficile
transmission are detailed below. The definitions and values of the parameters are outlined in
Table 1.
Lofgren et al. Page 9














Schematic representation of the compartmental flow of a mathematical model of the use of
fecal microbiota transplantation (FMT) to prevent incident and recurrent Clostridium
difficile infection (CDI). Inset indicates the potential routes of bacterial contamination
between patients and healthcare workers, whereas gray arrows indicate the movements
within the model influenced by the simulated intervention. Healthcare personnel are
classified as uncontaminated (US) or contaminated (H), and patients are classified into low
risk and uncolonized (Up), low risk and colonized (CP), high risk and uncolonized (UA),
high risk and colonized (CA), patients with CDI (D), and patients undergoing FMT (CT).
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A single stochastic realization of a mathematical model of the use of fecal microbiota
transplantation to prevent incident and recurrent Clostridium difficile infection (CDI). The
top panel shows the level of hand contamination in healthcare workers over a 24-hour
period, whereas the bottom 2 panels depict the number of patients and their current health
state over a 1-year period.
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Simulated recurrent and incident cases of Clostridium difficile infection (CDI) for 6 levels of
fecal microbiota transplantation after CDI to prevent the development of recurrence. All
simulation outcomes are shown, with the results summarized with box-and-whisker plots
depicting the median, 25th and 75th percentiles, and 1.5 times the interquartile range.
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Simulated recurrent and incident cases of Clostridium difficile infection (CDI) for 6 levels of
fecal microbiota transplantation after receipt of high-risk medication to prevent the
development of infection and recurrence among patients who received antibiotics or proton
pump inhibitors. All simulation outcomes are shown, with the results summarized with box-
and-whisker plots depicting the median, 25th and 75th percentiles, and 1.5 times the
interquartile range.
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Simulated recurrent and incident cases of Clostridium difficile infection (CDI) for 6 levels of
combined fecal microbiota transplantation (FMT) after receipt of high-risk medication to
prevent the development of infection and recurrence among patients who received
antibiotics or proton pump inhibitors and FMT after CDI to prevent the development of
recurrence. All simulation outcomes are shown, with the results summarized with box-and-
whisker plots depicting the median, 25th and 75th percentiles, and 1.5 times the interquartile
range.
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TABLE 1
Parameters for a Mathematical Model of the Use of Fecal Transplantation to Prevent Clostridium difficile
Infection (CDI) and Recurrence
Symbol Description Value Source
ι Handwashing rate 9.365 hand washes or glove
changes per hour
20–22
ρ Contact rate between patients and HCP 4.244 direct care tasks per
patient per hour
23
σi Probability that a healthcare provider’s hands are
contaminated by contact with a patient of type i
Low risk: 0.35; high risk: 0.35;
active infections: 0.50
24–27
Ψ Probability of transmission from contaminated HCP hands
to uncontaminated patient’s skin
0.90a 24
θi Discharge rate for an uninfected patient of type i High risk: 1/12.006 days; low
risk: 1/3.318 days
UNC Healthcare billing data
ζ Hourly probability of death for a patient with active CDI 0.000625 DICON cohort data
γ Hourly probability of discharge for a patient with active CDI 0.00188 DICON cohort data
νi Proportion of admitted patients who are of patient type i CP: 0.00447; CA: 0.0155; UP:
0.209; UA: 0.727; D: 0.044
UNC Healthcare billing data1,28
κ Hazard of developing CDI in low-risk, contaminated
patients
0.000208 DICON surveillance data
τ Relative risk of developing CDI due to high-risk medication 3.37 2,14,29
Φ Hourly probability of receiving postmedication FMT to
prevent incident infection or recurrence
Antibiotics only: 0.0011;
antibiotics and PPIs: 0.00169
UNC Healthcare billing data30–33
χ Percentage of eligible patients receiving fecal transplant 0–100 (varies by scenario)
ω Probability of a discharged patient developing recurrence 0.30 3
η Probability of fecal transplant in moving patient to low-risk
category
0.938 6
NOTE. CA, high-risk and colonized patients; CP, low-risk and colonized patients; D, patients with CDI; DICON, Duke Infection Control Outreach
Network; HCP, healthcare personnel; PPI, proton pump inhibitor; UA, high-risk and uncolonized patients; Up, low-risk and uncolonized patients;
UNC, University of North Carolina.
a
Assumed to be highly efficient on the basis of general agreement between skin sampling and hand culture methods, indicating a minimal loss of
contamination between touching a patient’s skin and deposition on another surface.
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TABLE 2
Patient Outcomes from a Mathematical Model of the Use of Fecal Transplantation to Prevent Clostridium
difficile Infection and Recurrence in a Simulated 12-Bed Intensive Care Unit over a 1-Year Period
Scenario, treatment level, %
Median recurrence (25th percentile, 75th
percentile) Pa
Median incidence (25th percentile, 75th
percentile) Pa
Baseline, 0 2 (0, 6) 0 (0, 1)
After infection
 20 1 (0, 4) <.001 0 (0, 1) .39
 40 1 (0, 4) 0 (0, 1)
 60 1 (0, 3) 0 (0, 1)
 80 0 (0, 1) 0 (0, 2)
 100 0 (0, 1) 0 (0, 1)
After receipt of high-risk medication (antibiotics)
 Antibiotics
  20 1 (0, 5) .36 0 (0, 1) .003
  40 1 (0, 6) 0 (0, 1)
  60 1 (0, 6) 0 (0, 1)
  80 2 (0, 6) 0 (0, 1)
  100 1 (0, 6) 0 (0, 1)
 Antibiotics and PPIs
  20 2 (0, 5.25) .56 0 (0, 1) .001
  40 2 (0, 6) 0 (0, 1)
  60 1 (0, 5) 0 (0, 1)
  80 2 (0, 5) 0 (0, 1)
  100 2 (0, 6) 0 (0, 1)
Combined
 20 1 (0, 5) <.001 0 (0, 1) .02
 40 1 (0, 4) 0 (0, 1)
 60 1 (0, 3) 0 (0, 1)
 80 0 (0, 2) 0 (0, 1)
 100 0 (0, 1) 0 (0, 1)
NOTE. PPI, proton pump inhibitor.
a
Kruskal-Wallis 1-way analysis of variance test.
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